The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) Enhances the Radiation Responsiveness of Lung and Colorectal Tumor Xenografts

Purpose: Novel molecularly targeted agents, given in combination with radiotherapy, have the potential to increase tumor response rates and the survival of patients with lung cancer. AZD6244 is a potent and selective inhibitor of mitogen-activated protein kinase (MAPK) kinase 1/2 (MEK1/2), a critical enzyme within the MAPK/extracellular signal-regulated kinase (ERK) signaling pathway that regulates the proliferation and survival of tumor cells. Experimental Design: This study examined the potential benefit of combining AZD6244 with fractionated radiotherapy using human lung and colon carcinoma xenograft models. Results: AZD6244 reduced ERK phosphorylation in Calu-6 lung cancer cells in vitro. Administration of AZD6244 for 10 days (25 mg/kg twice daily p.o.) inhibited the tumor growth of Calu-6 xenografts, with regrowth occurring on cessation of drug treatment. When fractionated tumor-localized radiotherapy (5 × 2 Gy) was combined with AZD6244 treatment, the tumor growth delay was enhanced significantly when compared with either modality alone, and this effect was also seen in a colon tumor model. We examined the effect of inhibiting MEK1/2 on the molecular responses to hypoxia, a potential interaction that could contribute to radioresponsiveness. AZD6244 reduced hypoxia-inducible factor–specific transactivation in vivo, shown using Calu-6 dual clone cells that stably express a Firefly luciferase gene under the control of a hypoxia-driven promoter. Furthermore, hypoxia-inducible factor-1α, GLUT-1, and vascular endothelial growth factor levels were reduced by AZD6244, and there was a significant decrease in vascular perfusion in the tumors given combination treatment when compared with the other treatment groups. Conclusions: These data provide support for the clinical development of AZD6244 in combination with radiotherapy and indicate a potential role for AZD6244 in inhibiting the tumor hypoxia response. (Clin Cancer Res 2009;15(21):6619–29)

[1]  Deborah Citrin,et al.  In vitro and In vivo Radiosensitization with AZD6244 (ARRY-142886), an Inhibitor of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase 1/2 Kinase , 2009, Clinical Cancer Research.

[2]  K. Williams,et al.  Antiangiogenics and radiotherapy , 2008, The Journal of pharmacy and pharmacology.

[3]  J. Hainsworth,et al.  Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC) , 2008 .

[4]  John D. Roberts,et al.  Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo , 2008, Molecular Cancer Therapeutics.

[5]  M. Herlyn,et al.  The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel , 2008, Clinical Cancer Research.

[6]  Paul D. Martin,et al.  AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models , 2007, Molecular Cancer Therapeutics.

[7]  S. Cook,et al.  Selective inhibition of MEK1/2 reveals a differential requirement for ERK1/2 signalling in the regulation of HIF-1 in response to hypoxia and IGF-1 , 2007, Oncogene.

[8]  R. Jain,et al.  Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatment-naive tumors. , 2007, Cancer research.

[9]  Mark W. Dewhirst,et al.  Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment , 2007, Cancer and Metastasis Reviews.

[10]  P. Harari,et al.  Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions , 2007, Nature Clinical Practice Oncology.

[11]  Vivienne Marsh,et al.  Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor , 2007, Clinical Cancer Research.

[12]  B. Telfer,et al.  Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit , 2007, Molecular Cancer Therapeutics.

[13]  P. Dent,et al.  Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. , 2007, Cancer research.

[14]  G. Panayotou,et al.  Identification of MAPK Phosphorylation Sites and Their Role in the Localization and Activity of Hypoxia-inducible Factor-1α* , 2006, Journal of Biological Chemistry.

[15]  J. Erler,et al.  Reversing Hypoxic Cell Chemoresistance in Vitro Using Genetic and Small Molecule Approaches Targeting Hypoxia Inducible Factor-1 , 2006, Molecular Pharmacology.

[16]  R. Seger,et al.  The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions , 2006, Growth factors.

[17]  J. Harmey,et al.  Angiogenic and cell survival functions of Vascular Endothelial Growth Factor (VEGF) , 2005, Journal of cellular and molecular medicine.

[18]  M. Beeram,et al.  Raf: a strategic target for therapeutic development against cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Dewhirst,et al.  Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. , 2005, Cancer cell.

[20]  M. Baumann,et al.  Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  A. Harris,et al.  Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[22]  B. Telfer,et al.  ZD6474, a Potent Inhibitor of Vascular Endothelial Growth Factor Signaling, Combined With Radiotherapy , 2004, Clinical Cancer Research.

[23]  M Paesmans,et al.  The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis , 2004, British Journal of Cancer.

[24]  Lei Xu,et al.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.

[25]  Susan M. Chang,et al.  Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. , 2004, International journal of radiation oncology, biology, physics.

[26]  M. Dewhirst,et al.  Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. , 2004, Cancer cell.

[27]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  N. Sang,et al.  MAPK Signaling Up-regulates the Activity of Hypoxia-inducible Factors by Its Effects on p300* , 2003, The Journal of Biological Chemistry.

[29]  L. Ellis,et al.  Insulin-like Growth Factor 1 Induces Hypoxia-inducible Factor 1-mediated Vascular Endothelial Growth Factor Expression, Which is Dependent on MAP Kinase and Phosphatidylinositol 3-Kinase Signaling in Colon Cancer Cells* , 2002, The Journal of Biological Chemistry.

[30]  Donald W Kufe,et al.  Vascular Endothelial Growth Factor Enhances Endothelial Cell Survival and Tumor Radioresistance , 2002, Cancer journal.

[31]  H. Esumi,et al.  Identification of Hypoxia-inducible Factor 1 Ancillary Sequence and Its Function in Vascular Endothelial Growth Factor Gene Induction by Hypoxia and Nitric Oxide* , 2001, The Journal of Biological Chemistry.

[32]  M Ancukiewicz,et al.  Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. , 2000, Cancer research.

[33]  G. Clark,et al.  The importance of being K-Ras. , 2000, Cellular signalling.

[34]  J. Pouysségur,et al.  Signaling Angiogenesis via p42/p44 MAP Kinase Cascade , 2000, Annals of the New York Academy of Sciences.

[35]  P. Wesseling,et al.  Amyloid‐β‐induced Degeneration of Human Brain Pericytes Is Dependent on the Apolipoprotein E Genotype , 2000, Annals of the New York Academy of Sciences.

[36]  D. Mottet,et al.  ERK activation upon hypoxia: involvement in HIF‐1 activation , 2000, FEBS letters.

[37]  R. Schmidt-Ullrich,et al.  Roles for basal and stimulated p21(Cip-1/WAF1/MDA6) expression and mitogen-activated protein kinase signaling in radiation-induced cell cycle checkpoint control in carcinoma cells. , 1999, Molecular biology of the cell.

[38]  J. Pouysségur,et al.  p42/p44 Mitogen-activated Protein Kinases Phosphorylate Hypoxia-inducible Factor 1α (HIF-1α) and Enhance the Transcriptional Activity of HIF-1* , 1999, The Journal of Biological Chemistry.

[39]  R. Weichselbaum,et al.  Blockade of the Vascular Endothelial Growth Factor Stress Response Increases the Antitumor Effects of Ionizing Radiation , 1999 .

[40]  A. Brunet,et al.  Nuclear translocation of p42/p44 mitogen‐activated protein kinase is required for growth factor‐induced gene expression and cell cycle entry , 1999, The EMBO journal.

[41]  Takashi Tsuruo,et al.  Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors , 1999, Oncogene.

[42]  P. Fisher,et al.  Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells , 1998, Oncogene.

[43]  B. Kavanagh,et al.  Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation , 1997, Oncogene.

[44]  G. Semenza,et al.  Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 , 1996, Molecular and cellular biology.

[45]  M. Sklar.  The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. , 1988, Science.

[46]  G. Duigou,et al.  Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways , 2001, Oncogene.

[47]  P. Dent,et al.  Ionizing radiation-induced mitogen-activated protein (MAP) kinase activation in DU145 prostate carcinoma cells: MAP kinase inhibition enhances radiation-induced cell killing and G2/M-phase arrest. , 2000, Radiation research.

[48]  R. Weichselbaum,et al.  Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. , 1999, Cancer research.

[49]  B. Fertil,et al.  Predictive value of in vitro radiosensitivity parameters in head and neck cancers and cervical carcinomas: preliminary correlations with local control and overall survival. , 1993, International journal of radiation oncology, biology, physics.